secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0000950170-22-015519
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.02, 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Q2 net income $18.5M; workforce cut 20%; CCO departure; Bayer deal terminated; FDA supports tab-cel BLA path
--------------------------------------------------------------------------------

- Net income $18.5M ($0.18/diluted) vs net loss $83.8M in Q2 2021; includes $50.2M gain on ATOM facility sale.
- Workforce reduction of ~20% to reduce future annual cash burn by >20%; expects $6M severance charges; cash runway extended to Q1 2024.
- Bayer termination agreement: Bayer pays $4.2M, returns rights to ATA2271/ATA3271; license and collab revenue $51.6M in Q2 from termination.
- FDA recommended pathway to BLA for tab-cel without new trial; EC approval on track Q4 2022.
- Kristin Yarema, SVP & CCO, to depart effective Nov 15, 2022; severance of 12 months base salary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017022015519/0000950170-22-015519-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017022015519/atra-20220802.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015519

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer